Michael W Thuransky, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 28 E Main St, Carnegie, PA 15106 Phone: 412-276-2610 |
Dr. James Lloyd Goodge Iii, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 1100 Washington Ave, Carnegie, PA 15106 Phone: 412-279-4040 Fax: 412-279-4041 |
Randour Chiropractic Clinic P.c. Chiropractor Medicare: Medicare Enrolled Practice Location: 1100 Washington Ave, Ste. 100, Carnegie, PA 15106 Phone: 412-279-4040 Fax: 412-279-4041 |
Carnegie Health & Wellness Center Chiropractor Medicare: Medicare Enrolled Practice Location: 8 E Main St, Carnegie, PA 15106 Phone: 412-276-2610 Fax: 412-276-2698 |
Dr. Donald Adam Robison, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 920 Washington Ave, Carnegie, PA 15106 Phone: 412-279-4040 Fax: 412-279-4041 |
News Archive
The high head impact and concussion rates in football are of increasing concern, especially for younger players.
A single overactive enzyme worsens the two core defects of diabetes—impaired insulin sensitivity and overproduction of glucose—suggesting that a drug targeting the enzyme could help correct both at once, according to mouse studies done by researchers at Columbia University Medical Center. The findings were published today in the online edition of Cell Metabolism.
A team led by researchers from Tianjin University has solved the structure of the Zika virus helicase, which is a key target for antiviral development. The research is published in Springer's journal Protein & Cell.
About one-third of women diagnosed with early-stage breast cancer will have their cancer travel, or metastasize, to other parts of the body, with the bone being the most common site of initial detectable spread. Controversy continues to surround the question of whether CT and bone scans should be standard in evaluating patients for these metastases, or whether integrated PET/CT scanning might be more effective at detecting breast tumors that have reached nearby bones.
Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced the receipt of a $4.0 million milestone payment from Pfizer Inc. under the terms of the collaboration agreement for the development of improved recombinant human Factor VIIa variants for the treatment of hemophilia and other bleeding disorders.
› Verified 2 days ago